Lisa van der Heijden

6PUBLICATIONS
10CO-AUTHORS
Molecular targetsPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersArtificial life and complex adaptive systems
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 20, 2025
Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib.

Ma Ida Mohmaed Ali, Lisa T van der Heijden, Matthijs Tibben

|Apr 30, 2024
The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.

Lisa T van der Heijden, Frans L Opdam, Jos H Beijnen

|Oct 13, 2023
The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib.

L T van der Heijden, N Steeghs, J H Beijnen

|Oct 04, 2023
Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Lisa T van der Heijden, Claire A Ribbers, Marit A C Vermunt

|Jul 28, 2023
Internet-Purchased Sodium Azide Used in a Fatal Suicide Attempt: A Case Report and Review of the Literature.

Lisa T van der Heijden, Karen E van den Hondel, Erik J H Olyslager

|Nov 24, 2022
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens.

Lisa van der Heijden, Merel van Nuland, Jos Beijnen

Pageof 1

Frequent Collaborators

2 joint publications

Thomas Dorlo

1 joint publications

Lutea A A de Jong

1 joint publications

Ma Ida Mohmaed Ali

1 joint publications

Hilde Rosing